spacer
home > ict > winter 2019 > improving outcomes in diabetes research
PUBLICATIONS
International Clinical Trials

Improving Outcomes in Diabetes Research

Diabetes is often referred to as an epidemic, with an estimated 415 million adults worldwide living with the condition, according to the International Diabetes Federation Diabetes Atlas – approximately 1 in 11 of the adult population (1). What’s more, this figure is expected to rise to 642 million people worldwide by 2040. With a reported 46% of people with diabetes undiagnosed, these figures are, realistically, much higher.

With so much of the population suffering, pharmaceutical companies are continuing to invest in research into this condition in a bid to bring new and improved treatments to market across the globe. With this in mind, this article will discuss the current status of diabetes clinical research. In particular, it will provide an overview of the current diabetes landscape, including the types of disease and condition management, as well as the challenges of clinical research. Putting the person with diabetes at the heart of the development process will demonstrate how sponsors can implement patient-centric electronic data capture solutions which improve the user experience and support better study outcomes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Katie Garner is the Therapeutic Areas Advisor at CRF Bracket. She is responsible for providing specific therapeutic advice and supporting the therapeutic, sales, marketing, and product development teams. Previously, Katie worked as a Project Manager for a health outcomes consultancy and at the NHS Purchasing and Supply Agencies Centre for Evidence-Based Purchasing. She has also worked for the Medicine and Healthcare products Regulatory Agency as a Senior Medical Device Specialist, responsible for the safety and regulation of in vitro diagnostic and contraceptive medical devices.
spacer
Katie Garner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement